SK Pharmteco Eyes US$2 bln Annual Sales by 2025 with Cell and Gene Therapy Biz

SEOUL, Jan. 11 (Korea Bizwire) — SK Pharmteco Inc., a biopharmaceutical arm of South Korea’s No. 3 conglomerate SK Group, aims to generate US$2 billion in annual sales in the next three years with a focus on cell and gene therapy business, its parent company SK Inc. said Tuesday. Aslam Malik, CEO of SK’s contract [...]